Company intelligence / Profile preview

Lyntonix

Ownership: Private
Development stage: Other

Overview

Lyntonix is developing first-in-class oral therapeutics targeting abdominal/visceral pain in irritable bowel syndrome. Their lead candidate has demonstrated potent and long-lasting analgesic effects with a high safety index in preclinical models. The company seeks co-development partners and aims to out-license after early clinical proof-of-concept studies expected to complete by or after 2027. No clinical results are available yet as programs are preclinical.[1][3]

Therapeutic areas: GastroenterologyNeurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

LTX-568

Preclinical

Partnerships

Seeking co-development partners but none disclosed yet.

Beyond the preview

Go deeper on Lyntonix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lyntonix.

Explore the full profile